<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596762</url>
  </required_header>
  <id_info>
    <org_study_id>814-PM-02</org_study_id>
    <nct_id>NCT03596762</nct_id>
  </id_info>
  <brief_title>A Study of NT-814 in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms</brief_title>
  <acronym>SWITCH-1</acronym>
  <official_title>A Double-Blind, Randomised, Placebo Controlled, Adaptive Design Study of the Efficacy, Safety and Pharmacokinetics of NT-814 in Female Subjects With Moderate to Severe Vasomotor Symptoms Associated With the Menopause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nerre Therapeutics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nerre Therapeutics Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of NT-814, taken once a day, in
      the treatment of troublesome post-menopausal symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centre, multi-country, double-blind, randomised, placebo-controlled Phase 2b
      study. The study will have a single-blind run-in period and will be adaptive with respect to
      the number of subjects recruited into each dose group.

      Four doses of NT-814 (40 mg once a day, 80 mg once a day, 120 mg once a day and 160 mg once a
      day) will be investigated and compared to placebo, in five parallel groups.

      Subjects will participate in the study for a total of approximately 19 weeks, comprising a
      screening period of 1 week, a 14 week treatment period, and then a final follow up visit 4
      weeks after the end of the treatment period. There will be a total of 8 visits whilst
      participating in the study.

      Subjects will record their hot flashes in an electronic diary during the screening period to
      establish eligibility and throughout the study after randomisation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Actual">December 13, 2019</completion_date>
  <primary_completion_date type="Actual">December 13, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in frequency of moderate and severe hot flashes recorded in patient diary</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in frequency of moderate and severe hot flashes recorded in patient diary</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in severity of moderate and severe hot flashes recorded in patient diary</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in severity of moderate and severe hot flashes recorded in patient diary</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Menopause</condition>
  <condition>Hot Flashes</condition>
  <condition>Night Waking</condition>
  <arm_group>
    <arm_group_label>NT-814 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160mg NT-814 capsules once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NT-814 120mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120mg NT-814 capsules once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NT-814 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80mg NT-814 capsules once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NT-814 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40mg NT-814 capsules once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules to match, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NT-814</intervention_name>
    <description>NT-814 capsules</description>
    <arm_group_label>NT-814 120mg</arm_group_label>
    <arm_group_label>NT-814 160mg</arm_group_label>
    <arm_group_label>NT-814 40mg</arm_group_label>
    <arm_group_label>NT-814 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Postmenopausal

          -  Body mass index between 18 and 38 kg/m2, inclusive

          -  Subject experiences moderate or severe hot flashes

        Key Exclusion Criteria:

          -  Inability to comply with the use of prohibited and allowed medications as described in
             the protocol.

          -  Any prior or ongoing history of clinically relevant drug or alcohol abuse within 12
             months of Screening.

          -  Any clinically significant prior or ongoing history of arrhythmias, either determined
             through clinical history or on ECG evaluation.

          -  Any clinically significant abnormal laboratory test result(s) measured at Screening.

          -  Any active ongoing condition that could have caused difficulty in interpreting
             vasomotor symptoms.

          -  Uncontrolled hypertension.

          -  A history or hyperthyroidism, hypothyroidism or abnormal thyroid function tests at
             Screening. Treated hypothyroidism with normal thyroid function test results at
             Screening is acceptable.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Study Site 12</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 19</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 13</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 15</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 18</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 10</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 11</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 17</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 50</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 51</name>
      <address>
        <city>Mission</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 54</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 52</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 53</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 37</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 34</name>
      <address>
        <city>Cannock</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 31</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 39</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 38</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 30</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 36</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 33</name>
      <address>
        <city>Poole</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 32</name>
      <address>
        <city>Southport</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 35</name>
      <address>
        <city>Stockton-on-Tees</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

